Tetraphase Pharmaceuticals

Tetraphase Pharmaceutical is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous, or IV, and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Company Growth (employees)
Type
Public
HQ
Watertown, US
Founded
2006
Size (employees)
66 (est)
Website
tphase.com
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US

Tetraphase Pharmaceuticals Office Locations

Tetraphase Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
110 480 Arsenal St

Tetraphase Pharmaceuticals Financials and Metrics

Tetraphase Pharmaceuticals Financials

Tetraphase Pharmaceuticals's revenue was reported to be $5.1 m in FY, 2016
USD

Revenue (Q3, 2017)

4.1 m

Net income (Q3, 2017)

(30 m)

EBIT (Q3, 2017)

(30.3 m)

Market capitalization (13-Dec-2017)

278.9 m

Cash (30-Sep-2017)

161.4 m
Tetraphase Pharmaceuticals's current market capitalization is $278.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.3 m9.1 m11.7 m5.1 m

Revenue growth, %

(50%)28%(56%)

EBIT

(112.8 m)(65.8 m)(83 m)(77.8 m)

EBIT margin, %

(617%)(723%)(710%)(1513%)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

2.2 m2.5 m1.3 m2.3 m3 m3.3 m2.9 m2 m1.2 m850 k1.5 m1.6 m4.1 m

R&D expense

10 m12.5 m16.5 m13.2 m18.9 m22.9 m17 m13.5 m13.7 m17.2 m25.9 m28.5 m28.8 m

General and administrative expense

1.9 m3.2 m2.9 m3.1 m4.9 m6.5 m3.9 m5.3 m4.8 m4.9 m5.1 m5.1 m5.6 m

Operating expense total

11.9 m15.7 m19.5 m16.3 m23.8 m29.4 m20.9 m18.8 m18.5 m22 m31.1 m33.6 m34.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

102.7 m121 m205.9 m142.1 m

Accounts Receivable

1.7 m3.5 m4.2 m1.8 m

Inventories

1 m2.1 m3.7 m6.6 m

Current Assets

105.4 m126.6 m213.8 m150.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

67.8 m89 m75.4 m56 m260.3 m242.1 m222.5 m189.9 m178.3 m162.1 m128.2 m118.2 m161.4 m

Accounts Receivable

2.1 m2 m1.3 m2 m5.5 m3.4 m3.1 m3.8 m3 m745 k1.7 m2.7 m3.6 m

Current Assets

72.1 m92.6 m78.5 m60.5 m268.9 m248.4 m228.1 m200.7 m186.5 m169.5 m133.7 m126 m170.4 m

PP&E

174 k238 k237 k314 k317 k946 k869 k948 k982 k932 k1.5 m1.5 m1.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(29.6 m)(66.7 m)(83.2 m)(77.5 m)

Depreciation and Amortization

129 k124 k193 k282 k

Accounts Receivable

746 k(1.8 m)(693 k)2.4 m

Inventories

(154 k)(1.2 m)(1.5 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.1 m)(13.5 m)(18.5 m)(14.2 m)(21 m)(26 m)(18 m)(16.7 m)(17.2 m)(21.1 m)(29.5 m)

Accounts Receivable

1.3 m2 m5.5 m3.4 m3.1 m3.8 m3 m745 k1.7 m

Accounts Payable

6.7 m3.7 m5.6 m5.8 m1.7 m1.5 m2.5 m3.6 m3.6 m
USDY, 2017

Revenue/Employee

61.6 k

Financial Leverage

1.2 x
Show all financial metrics

Tetraphase Pharmaceuticals Market Value History

Tetraphase Pharmaceuticals's Web-traffic and Trends

Tetraphase Pharmaceuticals Online and Social Media Presence

Tetraphase Pharmaceuticals Company Life and Culture

You may also be interested in